MPD-75

Pharmaceutical compound From Wikipedia, the free encyclopedia

MPD-75, also known as 1-methyl-N-pyrrolidyllysergamide or as 1-methyllysergic acid pyrrolidide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3][4] It is the 1-methyl derivative of lysergic acid pyrrolidide (LA-Pyr; LPD-824) and the N-pyrrolidide analogue of 1-methyl-LSD (MLD-41).[2] Extensive metabolism of other 1-methylated lysergamides to their secondary amine derivatives, for instance methysergide (1-methylmethylergometrine) conversion into methylergometrine, has been observed.[5][6]

Other namesMPD75; 1-Methyl-N-pyrrolidyllysergamide; 1-Methyllysergic acid pyrrolidide; 1-Methyl-LA-pyrrolidineamide; (1,6-Dimethyl-9,10-didehydroergolin-8β-yl)(pyrrolidin-1-yl)methanone
Routes of
administrationOral
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Quick facts Clinical data, Other names ...
MPD-75
Clinical data
Other namesMPD75; 1-Methyl-N-pyrrolidyllysergamide; 1-Methyllysergic acid pyrrolidide; 1-Methyl-LA-pyrrolidineamide; (1,6-Dimethyl-9,10-didehydroergolin-8β-yl)(pyrrolidin-1-yl)methanone
Routes of
administration		Oral
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • [(6aR,9R)-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinolin-9-yl]-pyrrolidin-1-ylmethanone
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H25N3O
Molar mass335.451 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C=C2[C@H]1CC3=CN(C4=CC=CC2=C34)C)C(=O)N5CCCC5
  • InChI=1S/C21H25N3O/c1-22-12-14-11-19-17(16-6-5-7-18(22)20(14)16)10-15(13-23(19)2)21(25)24-8-3-4-9-24/h5-7,10,12,15,19H,3-4,8-9,11,13H2,1-2H3/t15-,19-/m1/s1
  • Key:PWISINPCTJKXCA-DNVCBOLYSA-N
Close

Use and effects

MPD-75 was evaluated in humans and was found to produce partial LSD-like effects.[2][3][4] It was reported to have had a faster onset and shorter duration compared to LSD.[2] MPD-75 showed less than 5% of the potency of LSD in producing LSD-like effects, with a required dose of >20 μg/kg or >1.6 mg orally.[2][7][3][4] According to another source however, MPD-75 had 7% of the potency of LSD in humans.[8] For comparison, LA-Pyr (LPD-824) had approximately 10% of the potency of LSD and had more full LSD-like effects, while 1-methyl-LSD (MLD-41) had 33% of the potency of LSD and likewise produced full LSD-like effects.[2][3][4]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

In animal studies, MPD-75 had 4% of the toxicity of LSD in rabbits (presumably in terms of LD50Tooltip median lethal dose), 0% of its pyretogenic activity in rabbits, and 130% of its antiserotonergic activity in the isolated rat uterus.[8][9]

History

MPD-75 was first described in the scientific literature by Albert Hofmann and colleagues by 1957.[10][11] It has not been encountered as a designer drug as of 2020.[10]

See also

References

External links

Related Articles

Wikiwand AI